Evidence map›Paper›PMID 35886910›Full record

ReviewInternational journal of molecular sciences2022

Childhood B-Cell Preleukemia Mouse Modeling.

Marta Isidro-Hernández, Silvia Alemán-Arteaga, Ana Casado-García, Belén Ruiz-Corzo, Susana Riesco, Pablo Prieto-Matos, Jorge Martínez-Cano, Lucía Sánchez, César Cobaleda, Isidro Sánchez-García and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Editorial: Special Issue "Stem Cell Biology and Cancer".International journal of molecular sciences · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Marta Isidro-HernándezExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0001-8334-4981
Silvia Alemán-ArteagaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.
Ana Casado-GarcíaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.
Belén Ruiz-CorzoExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.
Susana RiescoInstitute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Pablo Prieto-MatosInstitute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0003-2680-3285
Jorge Martínez-CanoImmune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), 28049 Madrid, Spain.ORCID 0000-0001-6809-5489
Lucía SánchezSchool of Law, University of Salamanca, 37007 Salamanca, Spain.
César CobaledaImmune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), 28049 Madrid, Spain.ORCID 0000-0003-3807-9204
Isidro Sánchez-GarcíaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0001-6989-9905
Carolina Vicente-DueñasInstitute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-5401-8295
Instituto de Investigación Biomédica de Salamanca · ESComplejo Hospitalario de Salamanca · ESConsejo Superior de Investigaciones Científicas · ESUniversidad de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemia is the most usual childhood cancer, and B-cell acute lymphoblastic leukemia (B-ALL) is its most common presentation. It has been proposed that pediatric leukemogenesis occurs through a "multi-step" or "multi-hit" mechanism that includes both in utero and postnatal steps. Many childhood leukemia-initiating events, such as chromosomal translocations, originate in utero, and studies so far suggest that these "first-hits" occur at a far higher frequency than the incidence of childhood leukemia itself. The reason why only a small percentage of the children born with such preleukemic "hits" will develop full-blown leukemia is still a mystery. In order to better understand childhood leukemia, mouse modeling is essential, but only if the multistage process of leukemia can be recapitulated in the model. Therefore, mouse models naturally reproducing the "multi-step" process of childhood B-ALL will be essential to identify environmental or other factors that are directly linked to increased risk of disease.

Indexed as

Myelodysplastic SyndromesPrecursor Cell Lymphoblastic Leukemia-LymphomaPreleukemiaAnimalsDisease Models, AnimalHumansMiceTranslocation, Geneticchildhood leukemiagenetic predispositionleukemiamouse modelingpreleukemic cells

Identifiers

PMID35886910
PMCPMC9317949
OpenAlexW4284976504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.